FTC Approves Final Order Preserving Competition in Market for BRAF- and MEK-Inhibitor Oncology Drugs
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Novartis AG’s $16 billion acquisition of GlaxoSmithKline’s portfolio of cancer...